Synucleinopathy: Types, Symptoms, and Treatment

Synucleinopathies are a family of neurodegenerative diseases caused by the abnormal buildup of a protein called alpha-synuclein in the brain and nervous system. The group includes Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure, each affecting different cell types and brain regions in distinct ways. What links them is a shared molecular villain: clumps of misfolded alpha-synuclein that damage and eventually kill nerve cells. The clinical picture varies widely, from tremor and stiffness to hallucinations, cognitive decline, and drops in blood pressure upon standing, and a growing toolbox of biomarkers is changing how these conditions are detected.

How Alpha-Synuclein Goes Wrong

Alpha-synuclein is a small, naturally occurring protein found at nerve terminals throughout the brain, where it helps regulate the release of chemical signals between neurons. Problems begin when the protein misfolds and starts clumping together. For years, researchers assumed the large, mature clumps called fibrils were the main source of damage. But animal studies have shown that smaller, intermediate-sized clumps called oligomers are actually more toxic to dopamine-producing neurons than the fibrils themselves.¹ Laboratory work has further pinpointed a structural shift within the oligomers, from a loose initial form to a compact, protease-resistant shape, as the step that dramatically increases their ability to damage neurons through oxidative stress.²

Recent research has clarified how oligomers form in the first place. Rather than assembling directly from individual protein molecules, most oligomers appear to arise through a process called secondary nucleation, in which existing fibrils catalyze the creation of new oligomers on their surfaces.³ This means that once a small number of fibrils exist, they accelerate the production of the very oligomers that do the most harm, creating a self-reinforcing cycle of damage.

Where the Protein Accumulates Defines the Disease

What distinguishes one synucleinopathy from another is largely which cells the misfolded protein collects in and where those cells are located. In Parkinson’s disease and dementia with Lewy bodies, the protein aggregates mainly inside neurons, forming the round intracellular deposits known as Lewy bodies and the thread-like structures called Lewy neurites.⁴ In multiple system atrophy, the picture flips: the protein accumulates primarily in oligodendrocytes, the support cells that insulate nerve fibers, forming deposits called glial cytoplasmic inclusions. Neurons are affected too, but the oligodendroglial involvement is the hallmark.⁵

This cellular distinction matters because it drives the clinical differences between the diseases, the brain regions that degenerate, and ultimately how well patients respond to treatments.

The Major Types

Parkinson’s disease is the most common synucleinopathy, resulting from the death of dopamine-producing neurons in a region of the midbrain called the substantia nigra.⁶ The loss of dopamine leads to the cardinal motor symptoms: resting tremor, slowness of movement, rigidity, and postural instability. Non-motor features, including depression, constipation, sleep disturbance, and cognitive changes, are common and can precede motor symptoms by years.⁷

Dementia with Lewy bodies shares much of its underlying pathology with Parkinson’s but presents differently. The defining clinical boundary is timing: when dementia develops before or within a year of the onset of parkinsonism, the diagnosis is dementia with Lewy bodies. When cognitive decline surfaces more than a year after motor symptoms, it is called Parkinson’s disease dementia. This “one-year rule” is pragmatic rather than biological, and considerable heterogeneity exists within each diagnosis.⁸ Core features of dementia with Lewy bodies include fluctuating cognition, recurrent visual hallucinations, and parkinsonism.

Multiple system atrophy is rarer and more aggressive. It comes in two clinical subtypes based on the predominant symptom profile. The parkinsonian subtype, MSA-P, is characterized by stiffness and slowness that resemble Parkinson’s but respond poorly to levodopa. The cerebellar subtype, MSA-C, features unsteadiness, poor coordination, and slurred speech. Both subtypes carry severe autonomic dysfunction. In one cohort, MSA-P accounted for about 65% of cases and MSA-C for 35%, with median survival around nine years regardless of subtype.⁹ Brain imaging studies have shown that MSA-P involves progressive metabolic decline in the putamen, cerebellum, and frontal cortex, while MSA-C shows declines primarily in the cerebellum and frontal regions.¹⁰

Pure autonomic failure is the least common member of the family. It involves alpha-synuclein deposits primarily in the peripheral autonomic nervous system, causing severe drops in blood pressure on standing, urinary difficulties, and abnormal sweating, without the prominent motor or cognitive features seen in the other conditions. A fraction of people initially diagnosed with pure autonomic failure later convert to Parkinson’s disease, dementia with Lewy bodies, or multiple system atrophy.

Symptoms That Cross Diagnostic Boundaries

While each synucleinopathy has its signature features, many symptoms are shared across the group, which is one reason diagnosis can be so difficult in the early stages.

Visual hallucinations are a hallmark of Lewy body disease but occur in Parkinson’s disease as well, sometimes worsened by dopaminergic medications. Research distinguishes between minor visual hallucinations, such as fleeting shapes or a sense of presence, and complex formed hallucinations, like seeing people or animals. Minor hallucinations are not linked to cognitive impairment, but complex hallucinations are associated with impairments in visual perception, attention, and visual abstract reasoning.¹¹

Neuropsychiatric symptoms appear early and carry real prognostic weight. In Lewy body dementia, analysis of psychiatric symptom clusters has identified three main groupings: an affective component covering apathy and depression, a psychosis component covering delusions and hallucinations, and an anxiety component.¹² A related feature of Lewy body disease is fluctuating consciousness, periods of confusion and drowsiness that wax and wane unpredictably. Patients who show this pattern are significantly more likely to also have visual hallucinations, depression, and falls.¹³

Autonomic dysfunction is virtually universal across synucleinopathies. Neurogenic orthostatic hypotension, a sudden drop in blood pressure upon standing that causes dizziness or fainting, is especially prominent in multiple system atrophy and pure autonomic failure, and common in advanced Parkinson’s disease. Urinary urgency, constipation, and erectile dysfunction round out the picture.

REM Sleep Behavior Disorder as an Early Warning

One of the most striking advances in understanding synucleinopathies has been the recognition that a sleep disorder can precede full-blown disease by years or even decades. In REM sleep behavior disorder, the normal muscle paralysis that accompanies dreaming sleep is lost, causing people to act out their dreams, sometimes violently. Pathological studies indicate that alpha-synuclein pathology begins in brainstem nuclei responsible for REM-sleep muscle paralysis and later spreads to midbrain, limbic, and cortical regions.¹⁴

The conversion rate from isolated REM sleep behavior disorder to a diagnosed synucleinopathy is alarmingly high. One prospective study found that about a quarter of patients converted over a follow-up period averaging roughly three and a half years, with cumulative rates climbing to about 57% at ten years. Most converted to Parkinson’s disease, followed by dementia with Lewy bodies and then multiple system atrophy.¹⁵ Another multicenter analysis found conversion rates of 30% at three years and 66% at seven and a half years.¹⁶ This makes REM sleep behavior disorder the strongest known prodromal marker for synucleinopathy and a major focus for future preventive trials.

Diagnosis and Emerging Biomarkers

For most of their history, synucleinopathies could only be confirmed with certainty at autopsy. That is changing. A laboratory technique called the seed amplification assay detects tiny amounts of misfolded alpha-synuclein in body fluids and tissues by amplifying its signal, similar in concept to how a PCR test amplifies genetic material. In cerebrospinal fluid, this assay reaches 100% sensitivity for detecting Lewy body disease at the intermediate and advanced neuropathological stages, though sensitivity drops in earlier stages, hitting about 37% at the earliest Braak stages and about 73% at stage 3.¹⁷

A less invasive alternative is skin biopsy, which looks for phosphorylated alpha-synuclein in the small nerve fibers of the skin. A large multicenter study found that skin biopsy detected phosphorylated alpha-synuclein in roughly 93% of Parkinson’s disease cases, 96% of dementia with Lewy bodies cases, 98% of multiple system atrophy cases, and 100% of pure autonomic failure cases, while fewer than 4% of healthy controls tested positive.¹⁸ These are striking numbers for a simple punch biopsy. Seed amplification assays applied to skin biopsies similarly show high accuracy in established Parkinson’s disease, though sensitivity is lower in earlier stages of the disease.¹⁹

Seed amplification has also been tested in people with incidental Lewy body disease, a term for alpha-synuclein pathology found at autopsy in people who had no clinical diagnosis during life. In these cases, the cerebrospinal fluid assay was positive in about 76%, but sensitivity in skin and salivary gland tissue was much lower, around 35-38%.²⁰ This suggests that cerebrospinal fluid testing may be the most sensitive route for catching early, presymptomatic disease.

Imaging also plays an important role. Dopamine transporter SPECT scanning reveals reduced dopamine uptake in the striatum, helping distinguish Lewy body diseases from Alzheimer’s disease. Combining dopamine transporter SPECT with cardiac MIBG scintigraphy, which measures sympathetic nerve function in the heart, yields even better results. One study found the combined approach achieved over 96% sensitivity and about 91% specificity in separating dementia with Lewy bodies from Alzheimer’s disease.²¹

Treatment of Symptoms

No treatment yet cures or reverses any synucleinopathy. Current management focuses on relieving symptoms, and responses differ sharply between diseases.

Levodopa, a precursor to dopamine, remains the most effective drug for the motor symptoms of Parkinson’s disease. In a large clinicopathological study, about 86% of people with confirmed Parkinson’s disease showed a definite response to levodopa, and that response carried prognostic significance: definite responders had roughly 55% fewer falls, 69% lower risk of dementia, and 69% better survival compared to those who did not respond clearly.²² By contrast, only about 8% of people with multiple system atrophy showed a definite levodopa response, and for those few who did, it did not translate into better long-term outcomes on disease milestones.²² This difference is so consistent that levodopa responsiveness has diagnostic value: a definite response distinguishes Parkinson’s disease from multiple system atrophy with about 86% sensitivity and 96% specificity.

For neurogenic orthostatic hypotension, the FDA-approved drug droxidopa provides a way to boost norepinephrine levels. It is a synthetic amino acid that the body converts into norepinephrine, raising blood pressure by increasing vascular tone.²³ Droxidopa has been used in Japan since 1989 for orthostatic hypotension in Parkinson’s disease and multiple system atrophy and was later approved in the United States for symptomatic neurogenic orthostatic hypotension broadly.²⁴ Other interventions for blood pressure drops include midodrine, increased salt and fluid intake, compression garments, and sleeping with the head of the bed elevated.

Cholinesterase inhibitors, originally developed for Alzheimer’s disease, are often used to manage cognitive symptoms and hallucinations in dementia with Lewy bodies. Antipsychotics, by contrast, must be used with extreme caution in Lewy body diseases because patients are severely sensitive to their side effects, which can include dangerous rigidity and worsening confusion.

Deep Brain Stimulation

For Parkinson’s disease patients whose motor symptoms are no longer well controlled by medication, deep brain stimulation of the subthalamic nucleus is a well-established surgical option. A recent five-year outcomes study found that motor function in the off-medication state improved by about 51% at one year and still showed a 36% improvement at five years. Involuntary movements caused by medication, known as dyskinesias, dropped by roughly 75% at one year and remained about 70% lower at five years. Meanwhile, the total daily dose of levodopa was reduced by about 28%, a reduction that held steady through year five.²⁵ Deep brain stimulation does not slow the underlying disease, but it can substantially improve quality of life and reduce medication burden for selected patients. It is not routinely used in multiple system atrophy or dementia with Lewy bodies, where the risk-benefit profile is much less favorable.

Disease-Modifying Therapies Under Investigation

The treatments described above manage symptoms without addressing the underlying protein aggregation. The search for therapies that slow or stop disease progression is one of the most active fronts in neurology.

Immunotherapy is the most advanced approach. Several vaccines and monoclonal antibodies targeting alpha-synuclein are in clinical trials. Prasinezumab, a monoclonal antibody that binds aggregated alpha-synuclein, has shown the most encouraging signals. In a trial of people with early-stage Parkinson’s disease who were already taking a type of medication called MAO-B inhibitors, prasinezumab slowed motor progression by about 39% over one year compared to placebo.²⁶ The effect was smaller in treatment-naive patients. Other antibody programs, including cinpanemab, have been discontinued after failing to meet primary endpoints, and the field recognizes that variable efficacy and trial discontinuations remain persistent challenges.²⁷

A different strategy targets the lysosomal system, the cellular machinery that normally breaks down and recycles damaged proteins. Mutations in the GBA1 gene, which codes for the enzyme glucocerebrosidase, are the most common genetic risk factor for Parkinson’s disease, and they impair the cell’s ability to clear alpha-synuclein. In animal models, gene therapy that increases glucocerebrosidase activity has been shown to reduce alpha-synuclein accumulation and protect dopamine neurons from degeneration.²⁸ More recently, researchers have identified a related enzyme, acid ceramidase, as a potential drug target. Inhibiting or genetically reducing this enzyme in dopamine neurons carrying GBA1 mutations reversed multiple abnormalities related to alpha-synuclein clearance.²⁹ These lysosomal approaches are still in preclinical or early clinical stages but represent a mechanistically distinct avenue from immunotherapy.

Genetic and Environmental Risk Factors

Most synucleinopathies are sporadic, meaning they arise without a clear inherited cause. But genetics plays a role on a spectrum. Rare, highly penetrant mutations in the SNCA gene, which encodes alpha-synuclein itself, cause autosomal dominant forms of Parkinson’s disease and dementia with Lewy bodies. These include point mutations and duplications or triplications of the gene, with extra copies leading to earlier onset and more severe disease.³⁰ More common are variants in SNCA and other genes, such as GBA1 and LRRK2, that modestly increase risk without guaranteeing disease.

Environmental exposures interact with genetic susceptibility. Pesticides and the industrial solvent trichloroethylene are the most studied environmental risk factors for parkinsonism.³¹ Genetic variations in SNCA appear to modify the risk associated with pesticide exposure, and the interaction may be particularly relevant in younger-onset cases.³²

The Prion-Like Spread and the Gut-Brain Connection

One of the most consequential ideas in synucleinopathy research is that misfolded alpha-synuclein spreads through the nervous system in a manner resembling prion diseases. The concept builds on the observation, first systematically described by Braak and colleagues, that Lewy pathology appears to follow a predictable route through the brain, starting in lower brainstem and olfactory structures and ascending to midbrain, limbic, and eventually cortical areas. Laboratory and animal evidence has shown that alpha-synuclein can transfer from one cell to another and induce normal protein to misfold, a process called permissive templating.³³ This cell-to-cell propagation appears to occur through normal cellular secretion and uptake pathways.³⁴

Where might the process begin? Alpha-synuclein deposits have been consistently found in the gut of Parkinson’s disease patients, leading to the hypothesis that the disease may sometimes start in the gastrointestinal tract and travel to the brain through the vagus nerve, a direct anatomical highway between the gut and the brainstem.³⁵ This “gut-first” model does not apply to every patient; some people appear to develop brain pathology without early gut involvement. But it has generated intense interest because of its implications for early detection and, potentially, for intercepting the disease before it reaches the brain.

Neuroinflammation as a Driver

For a long time, inflammation in the brain was considered a bystander effect, a consequence of neuronal death rather than a cause. That view has shifted. The brain’s resident immune cells, microglia, respond to extracellular alpha-synuclein by becoming activated and releasing inflammatory signals. The enzyme LRRK2, whose gene is one of the most important genetic risk factors for Parkinson’s disease, plays a critical role in this response. Blocking LRRK2 in laboratory models markedly reduced the inflammatory neurotoxicity triggered by alpha-synuclein.³⁶

Even more strikingly, transplanting microglia that had been activated by alpha-synuclein into the brains of otherwise healthy mice was sufficient to trigger full-blown synucleinopathy, including protein aggregation, gliosis, neuroinflammation, and behavioral changes, and the pathology spread beyond the transplant site to larger brain regions.³⁷ These findings suggest that inflammation is not just along for the ride but plays an early, active role in driving disease. Multiple LRRK2 inhibitors are now in clinical trials, in part because of the promise of dampening this inflammatory cascade alongside the protein-spreading process.